Recent News

• 03.11.2025 - Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
• 03.11.2025 - Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program
• 03.07.2025 - Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
• 03.07.2025 - Achieve Life Sciences to Present at the Barclays 27th Annual Global Healthcare Conference
• 03.06.2025 - Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
• 03.06.2025 - Achieve Life Sciences to Announce Fourth Quarter and Year-End 2024 Financial Results and Host Conference Call and Webcast on March 11, 2025
• 02.11.2025 - Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
• 02.11.2025 - Achieve Life Sciences to Present at the Oppenheimer Healthcare Life Sciences Conference
• 02.10.2025 - Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial
• 02.10.2025 - Achieve Life Sciences Announces Positive Outcome of Second Data Safety Monitoring Committee Review for the ORCA-OL Clinical Trial

Recent Filings

• 03.11.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.11.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report
• 02.10.2025 - EX-99.1 EX-99.1
• 02.10.2025 - 8-K Current report
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities
• 01.30.2025 - 4 Statement of changes in beneficial ownership of securities